Pfizer (NYSE:PFE) Trading Down 0.5% – Should You Sell?

Pfizer Inc. (NYSE:PFE)’s share price dropped 0.5% on Monday . The company traded as low as $28.85 and last traded at $29.00. Approximately 5,136,444 shares were traded during mid-day trading, a decline of 86% from the average daily volume of 37,227,152 shares. The stock had previously closed at $29.16.

Analyst Ratings Changes

Several research firms have weighed in on PFE. Barclays increased their target price on shares of Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research note on Thursday, October 3rd. StockNews.com upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Wednesday, October 9th. Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Finally, UBS Group raised their target price on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a report on Wednesday, July 31st. Eight analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $34.54.

Pfizer Trading Down 0.4 %

The company has a market cap of $164.61 billion, a P/E ratio of -483.33, a price-to-earnings-growth ratio of 1.30 and a beta of 0.67. The firm has a 50-day moving average of $29.04 and a 200 day moving average of $28.39. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. The business had revenue of $13.28 billion during the quarter, compared to the consensus estimate of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The firm’s revenue for the quarter was up 2.1% on a year-over-year basis. During the same period in the previous year, the company posted $0.67 earnings per share. On average, analysts predict that Pfizer Inc. will post 2.66 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be given a dividend of $0.42 per share. The ex-dividend date is Friday, November 8th. This represents a $1.68 annualized dividend and a dividend yield of 5.78%. Pfizer’s payout ratio is -2,800.00%.

Institutional Trading of Pfizer

Several hedge funds have recently made changes to their positions in the company. GenWealth Group Inc. bought a new stake in Pfizer in the 3rd quarter valued at about $278,000. Creative Planning lifted its stake in shares of Pfizer by 17.1% during the 3rd quarter. Creative Planning now owns 1,820,731 shares of the biopharmaceutical company’s stock valued at $52,692,000 after buying an additional 266,167 shares in the last quarter. CX Institutional boosted its holdings in Pfizer by 80.1% in the 3rd quarter. CX Institutional now owns 46,207 shares of the biopharmaceutical company’s stock worth $1,337,000 after buying an additional 20,552 shares during the period. Fiduciary Alliance LLC grew its stake in Pfizer by 15.5% in the 3rd quarter. Fiduciary Alliance LLC now owns 8,484 shares of the biopharmaceutical company’s stock valued at $246,000 after buying an additional 1,140 shares in the last quarter. Finally, ORG Partners LLC raised its holdings in Pfizer by 1.9% during the 3rd quarter. ORG Partners LLC now owns 47,912 shares of the biopharmaceutical company’s stock valued at $1,387,000 after acquiring an additional 884 shares during the period. 68.36% of the stock is currently owned by institutional investors.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.